Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GH35 in KRAS G12C-mutated advanced solid tumors
CTR20222296Phase 2Completed
- Sponsor
- Qinhao Pharmaceutical (Suzhou) Co., Ltd.
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GH35 in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer (PC), cholangiocarcinoma (CCA), Cervical Cancer (CC), sponsored by Qinhao Pharmaceutical (Suzhou) Co., Ltd.. Started Sep 2022; status: completed.
02
Drugs
GH35
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic cancer (PC)cholangiocarcinoma (CCA)Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20222296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222296.